Levodopa and Carbidopa
Levodopa and carbidopa is a combination medicine used to treat Parkinson’s disease and related parkinsonism, including parkinsonism that may follow carbon monoxide or manganese poisoning, and motor fluctuations in advanced Parkinson’s disease (Duopa).
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 67 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Levodopa and carbidopa, on the U.S. market for decades and available generically, is the most effective treatment for the symptoms of Parkinson’s disease and related parkinsonism; levodopa becomes dopamine in the brain, and carbidopa keeps it from breaking down elsewhere in the body so more gets there. Most people tolerate it well, noticing nausea or dizziness at first, while uncontrolled movements (dyskinesia) tend to show up after years of use. Report falling asleep suddenly during daily activities, new hallucinations or compulsive urges to gamble or spend right away, and never stop it or cut the dose quickly, which can trigger a dangerous reaction with fever and stiff muscles.
Clinical pearls
- High-protein meals can reduce how well levodopa is absorbed, so a dose taken with a big steak dinner may seem weaker.
- Iron supplements, including multivitamins with iron, can reduce absorption, so avoid taking them at the same time as your dose.
- Never chew or crush the extended-release forms, and never switch between Sinemet, Rytary or Crexont on your own.
- Metoclopramide, a common nausea medicine, and many antipsychotics can worsen Parkinson’s control, so remind hospital and ER staff you take this.
Patient information guide A plain-language walkthrough of Levodopa and Carbidopa, written from its FDA label.
What Levodopa and Carbidopa is used for
▾
Levodopa and carbidopa treats several forms of parkinsonism.
- Parkinson’s disease (oral tablets, orally disintegrating tablets, and extended-release tablets and capsules)
- Post-encephalitic parkinsonism
- Parkinsonism that may follow carbon monoxide or manganese intoxication
- Duopa (enteral suspension): motor fluctuations in advanced Parkinson’s disease
- Crexont: labeled for adults
How Levodopa and Carbidopa works
▾
Parkinson’s symptoms are tied to low dopamine in the brain. Levodopa crosses into the brain and is presumably converted to dopamine. Carbidopa stays outside the brain and blocks levodopa’s early breakdown, so more reaches the brain. This lets doctors use lower levodopa doses.
Levodopa and Carbidopa dosage
▾
Dosing is individualized by slow adjustment, so follow your prescriber and label.
- Tablets, extended-release tablets and capsules are taken by mouth; orally disintegrating tablets dissolve on the tongue.
- Don’t chew or crush extended-release products.
- Rytary and Crexont can be taken with or without food.
- Duopa is delivered into the small intestine by a pump through a tube.
- Don’t stop suddenly.
Dosing details from the FDA-approved label
From the Levodopa and Carbidopa prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Patients currently treated with conventional carbidopa-levodopa preparations (extended-release tablets)
- Substitute at an amount that provides approximately 10% more levodopa per day, may need to be increased to provide up to 30% more levodopa per day depending on clinical response
- Interval between doses 4-8 hours during the waking day
- Conversion guide: 300-400 mg levodopa total daily dose = 200 mg b.i.d
- 500-600 = 300 mg b.i.d. or 200 mg t.i.d
- 700-800 = a
- Bioavailability of extended-release tablets is approximately 0.70-0.75 vs 0.99 for immediate-release
- Patients currently treated with levodopa without a decarboxylase inhibitor (extended-release tablets)
- Discontinue levodopa at least twelve hours before starting
- Substitute a dosage that will provide approximately 25% of the previous levodopa dosage
- In mild to moderate disease, initial dose is usually 1 tablet of 50 mg/200 mg b.i.d
- Patients not receiving levodopa, mild to moderate disease (extended-release tablets)
- 1 tablet of 50 mg/200 mg b.i.d
- Initial dosage should not be given at intervals of less than 6 hours
- Titration of carbidopa and levodopa extended-release tablets
- Most patients adequately treated with doses providing 400 to 1600 mg of levodopa per day in divided doses at intervals of 4 to 8 hours during the waking day
- At least 3 days between dosage adjustments recommended
- Maximum: Higher doses (2400 mg or more of levodopa per day) and shorter intervals (less than 4 hours) have been used but are not usually recommended
- If doses are given at intervals of less than 4 hours and/or divided doses are not equal, give the smaller doses at the end of the day
- Duopa (enteral suspension) daily dose
- Administered over a 16-hour infusion via PEG-J with the CADD-Legacy 1400 pump
- Individually titrated daily dose composed of a Morning Dose, a Continuous Dose and Extra Doses
- Night-time dose is oral immediate-release carbidopa-levodopa tablets
- Maximum: 2000 mg of levodopa (one cassette per day) administered over 16 hours
- Evaluate vitamin B6 levels before starting
- Duopa extra doses
- Extra dose function set at 1 mL (20 mg of levodopa) when starting
- Adjusted typically in 0.2 mL increments
- Maximum: Limited to one extra dose every 2 hours
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Evaluate vitamin B6 levels prior to starting treatment with carbidopa/levodopa therapies. ( 2.1 ) The maximum recommended daily dose of DUOPA is 2000 mg of levodopa (i.e., one cassette per day) administered over 16 hours ( 2.2) Prior to initiating DUOPA, convert patients from all forms of levodopa to oral immediate-release carbidopa-levodopa tablets (1:4 ratio) ( 2.3 ) Titrate total daily dose based on clinical response for the patient ( 2.3 ) Administer DUOPA into the jejunum through a percutaneous endoscopic gastrostomy with jejunal tube (PEG-J) with the CADD®-Legacy 1400 portable infusion pump ( 2.4) 2.1 Management of Vitamin B6 Levels Evaluate vitamin B6 levels prior to initiating carbidopa/levodopa therapies including DUOPA, periodically during treatment, and as clinically indicated [see Warnings and Precautions ( 5.9 )] . If vitamin B6 levels are low, supplement to sufficient levels per standard of care. Patients may initiate and continue treatment with DUOPA while supplementing vitamin B6. 2. 2 DUOPA Daily Dose DUOPA is administered over a 16-hour infusion period. The daily dose is determined by individualized patient titration and composed of: A Morning Dose A Continuous Dose Extra Doses The maximum recommended daily dose of DUOPA is 2000 mg of the levodopa component (i.e., one cassette per day) administered over 16 hours. At the end of the daily 16-hour infusion, patients will disconnect the pump from the PEG-J and take their night-time dose of oral immediate-release carbidopa-levodopa tablets. Treatment with DUOPA is initiated in 3 steps [see Dosage and Administration ( 2.3 ) ] : Conversion of patients to oral immediate-release carbidopa-levodopa tablets in preparation for DUOPA treatment. Calculation and administration of the DUOPA starting dose (Morning Dose and Continuous Dose) for Day 1. Titration of the dose as needed based on individual clinical response and tolerability. Extra Doses DUOPA has an extra dose function that can be used to manage acute “Off” symptoms that are not controlled by the Morning Dose and the Continuous Dose administered over 16 hours. The extra dose function should be set at 1 mL (20 mg of levodopa) when starting DUOPA. If the amount of the extra dose needs to be adjusted, it is typically done in 0.2 mL increments. The extra dose frequency should be limited to one extra dose every 2 hours.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Levodopa and Carbidopa side effects
▾
Common side effects seen in studies include:
Common side effects
- Dyskinesia (uncontrolled movements)
- Nausea
- Hallucinations
- Confusion
- Dizziness
- Depression
- Headache
- Vivid or abnormal dreams
When to get medical help
- Call your doctor right away if you fall asleep suddenly during daily activities or have significant daytime sleepiness.
- Get help for hallucinations, paranoia, delusions, agitation, or severe confusion.
- Tell your doctor about intense urges to gamble, spend, eat, or have sex that you can’t control.
- Report depression or thoughts of suicide right away.
- Get urgent help for fever, stiff muscles, confusion, or altered awareness, especially after a dose is cut back or stopped.
- Seek care for chest pain or an irregular heartbeat.
- With Duopa, call right away for abdominal pain, prolonged constipation, nausea, vomiting, fever, or black stools.
- Report numbness, tingling, or seizures, which can be linked to low vitamin B6.
Act quickly on sudden sleep episodes, severe mood or behavior changes, compulsive urges, fever with stiffness, chest pain, or seizures.
Levodopa and Carbidopa warnings and precautions
▾
- Sudden sleep onset can occur without warning, even after long use.
- Hallucinations, psychosis, and confusion may occur and can respond to dose reduction.
- Compulsive urges such as gambling, spending, eating, or sexual urges can develop.
- Watch for depression and suicidal thoughts.
- Abrupt dose reduction or stopping can cause fever, rigidity, and confusion.
- Low vitamin B6 can cause seizures and neuropathy.
- Low blood pressure on standing, dyskinesia, and heart rhythm problems may occur.
- Duopa carries risks from the tube procedure, which can be serious.
Levodopa and Carbidopa interactions
▾
Several medicines can change how levodopa and carbidopa work.
- Nonselective MAO inhibitors: contraindicated with the extended-release tablets.
- Selegiline: may cause severe low blood pressure on standing.
- Blood pressure medicines: may need adjustment.
- Antipsychotics, isoniazid, phenytoin, papaverine: may reduce levodopa’s effect.
- Reserpine, tetrabenazine: not recommended with extended-release tablets.
- Iron: may reduce absorption.
- Metoclopramide: may worsen disease control.
- High-protein meals: may reduce levodopa absorption.
- Alcohol: Crexont should not be taken with alcohol.
Interactions listed in the FDA-approved label
From the Levodopa and Carbidopa prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Antihypertensive drugs: Symptomatic postural hypotension has occurred when carbidopa and levodopa preparations were added to some antihypertensive drugs. Dosage adjustment of the antihypertensive drug may be required when therapy is started.
- MAO inhibitors (Type A or B), including selegiline: Concomitant selegiline therapy may be associated with severe orthostatic hypotension not attributable to carbidopa and levodopa alone. See CONTRAINDICATIONS.
- Tricyclic antidepressants: Rare reports of adverse reactions, including hypertension and dyskinesia. Caution should be exercised.
- Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid: May reduce the therapeutic effects of levodopa. Carefully observe for loss of therapeutic response.
- Phenytoin and papaverine: The beneficial effects of levodopa in Parkinson's disease have been reported to be reversed. Carefully observe for loss of therapeutic response.
- Dopamine-depleting agents (e.g., reserpine and tetrabenazine) or other drugs that deplete monoamine stores: Concomitant use with the extended-release tablets is addressed as not recommended. Use is not recommended.
- Iron salts or multivitamins containing iron salts: Iron salts can form chelates with levodopa and carbidopa and reduce their bioavailability. Coadminister with caution.
- Metoclopramide: May increase levodopa bioavailability by increasing gastric emptying, but may also adversely affect disease control through its dopamine receptor antagonistic properties.
Read the label’s full interactions text
Drug Interactions Caution should be exercised when the following drugs are administered concomitantly with carbidopa and levodopa extended-release tablets. Symptomatic postural hypotension has occurred when carbidopa and levodopa preparations were added to the treatment of patients receiving some antihypertensive drugs. Therefore, when therapy with carbidopa and levodopa extended-release tablets is started, dosage adjustment of the antihypertensive drug may be required. For patients receiving MAO inhibitors (Type A or B), see CONTRAINDICATIONS . Concomitant therapy with selegiline and carbidopa and levodopa may be associated with severe orthostatic hypotension not attributable to carbidopa and levodopa alone (see CONTRAINDICATIONS ). There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa and levodopa preparations. Dopamine D 2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa. In addition, the beneficial effects of levodopa in Parkinson’s disease have been reported to be reversed by phenytoin and papaverine. Patients taking these drugs with carbidopa and levodopa extended-release tablets should be carefully observed for loss of therapeutic response. Use of carbidopa and levodopa extended-release tablets with dopamine-depleting agents (e.g., reserpine and tetrabenazine) or other drugs known to deplete monoamine stores is not recommended. Carbidopa and levodopa extended-release tablets and iron salts or multivitamins containing iron salts should be coadministered with caution. Iron salts can form chelates with levodopa and carbidopa and consequently reduce the bioavailability of carbidopa and levodopa.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Levodopa and Carbidopa
▾
- Narrow-angle glaucoma or allergy to an ingredient (extended-release tablets contraindicated).
- Severe heart, lung, kidney, liver or hormone disease, or asthma.
- Past heart attack with irregular heartbeat, or a history of peptic ulcer.
- Major psychotic disorder (Duopa should not be used).
- Pregnancy: animal studies showed fetal harm.
- Breastfeeding: levodopa passes into milk and may reduce milk supply.
- Children: safety and effectiveness not established.
- Older adults: no overall differences seen in extended-release capsule trials.
Levodopa and Carbidopa overdose
▾
For overdose of the extended-release tablets, management is the same as for levodopa. This includes supportive care, careful fluids, airway protection, and heart monitoring for arrhythmias. Pyridoxine (vitamin B6) does not reverse the effects. Seek emergency help or call poison control right away.
What Levodopa and Carbidopa does in the body
▾
When taken by mouth, levodopa is rapidly converted to dopamine outside the brain, so only a small portion reaches it. Carbidopa blocks this conversion, so more levodopa gets to the brain. Extended-release tablets give steadier levodopa levels than regular tablets, though they are less bioavailable and may need higher daily doses.
How your body processes Levodopa and Carbidopa
▾
Carbidopa lowers the levodopa needed by about 75% and extends levodopa’s time in the blood. Levodopa’s half-life with carbidopa is roughly 1.5 to 2 hours. Extended-release capsules reach peak levels later and lower than immediate-release tablets. A high-fat meal can delay absorption by about 2 hours, and a high-protein meal may decrease it. Levodopa is broken down by two main pathways, and carbidopa leaves mainly in the urine.
How to store Levodopa and Carbidopa
▾
Store in freezer at -20 o C (-4 o F). refrigerator at 2 o C to 8 o C (36 o F to 46 o F) prior to dispensing. refrigerator to thaw.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Levodopa and Carbidopa
43 supplements and herbal products have documented interactions with Levodopa and Carbidopa in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 8
- Moderate · 24
- Minor · 11
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Levodopa and Carbidopa has been associated with lower levels of 2 nutrients in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
- Higher significance · 1
- Moderate · 1
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Levodopa and Carbidopa: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Levodopa and Carbidopa — the kind of thing our pharmacy team would talk through with you at the counter.
What is this medicine for?
▾
How should I take it?
▾
What side effects should I expect?
▾
Can I drive on this medicine?
▾
Can I stop it if I feel better?
▾
Are there medicines or supplements I should watch out for?
▾
Is Levodopa and Carbidopa available over the counter?
▾
When was Levodopa and Carbidopa first available?
▾
Who makes Levodopa and Carbidopa?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Levodopa and Carbidopa on HelloPharmacist
Levodopa and Carbidopa forms and strengths (how it comes)
Levodopa and Carbidopa is available in 5 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Sinemet is used for Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism after carbon monoxide or manganese intoxication.
- Sinemet dosing is adjusted by careful titration for each patient.
- Sinemet comes in more than one carbidopa-to-levodopa ratio, which may be used separately or combined.
- Sinemet requires vitamin B6 levels to be evaluated before and during treatment.
Extended-release tablet
How this form is used
- Carbidopa and Levodopa extended-release tablets are used for Parkinson’s disease and related parkinsonism.
- Carbidopa and Levodopa extended-release tablets should not be chewed or crushed.
- The daily dose is set by careful titration, with close monitoring for involuntary movements or nausea.
Extended-release capsule
How this form is used
- Crexont is used in adults for Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism after carbon monoxide or manganese intoxication.
- Rytary is used for Parkinson’s disease and related parkinsonism.
- Rytary may be taken with or without food; do not chew, divide or crush.
- Crexont may be taken with or without food; do not chew, divide or crush, and avoid alcohol.
- Rytary and Crexont doses are not interchangeable with other carbidopa-levodopa products.
Show 6 more strengths Show fewer strengths
Orally disintegrating tablet
How this form is used
- Carbidopa and Levodopa orally disintegrating tablets are used for Parkinson’s disease and related parkinsonism.
- Carbidopa and Levodopa orally disintegrating tablets: remove gently with dry hands and place on top of the tongue right away.
- They dissolve in seconds and are swallowed with saliva; no liquid is needed.
Oral suspension
How this form is used
- Duopa is used for motor fluctuations in people with advanced Parkinson’s disease.
- Duopa is given into the small intestine through a PEG-J tube using a portable infusion pump.
- Duopa’s maximum daily amount is one cassette, given over 16 hours.
- Vitamin B6 levels should be checked before starting Duopa and periodically.
Levodopa and Carbidopa on the U.S. market: products, makers and brands
How Levodopa and Carbidopa appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
36 companies list 118 Levodopa and Carbidopa product records with the FDA, mostly as tablet, extended-release tablet, extended-release capsule; the earliest marketing or approval year on record is 1999. Brand names on the directory include Duopa, Rytary, Sinemet and 2 more; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Levodopa and Carbidopa is used (Medicaid data)
A general measure of how commonly Levodopa and Carbidopa is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Levodopa and Carbidopa is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Levodopa and Carbidopa prescribed? Of the 1,601 medications we measure, Levodopa and Carbidopa ranks #441 by Medicaid prescriptions — more than 72% of them.
Utilization by Levodopa and Carbidopa product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
carbidopa 25 MG / levodopa 100 MG Oral Tablet Most dispensed
Summed across the 26 of 106 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 197444
carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet
Summed across the 5 of 39 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 308989
carbidopa 25 MG / levodopa 250 MG Oral Tablet
Summed across the 14 of 71 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 197445
carbidopa 25 MG / levodopa 100 MG Extended Release Oral Tablet
Summed across the 5 of 35 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 308988
carbidopa 10 MG / levodopa 100 MG Oral Tablet
Summed across the 12 of 59 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 197443
8 HR carbidopa 48.75 MG / levodopa 195 MG Extended Release Oral Capsule
Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1600914
8 HR carbidopa 36.25 MG / levodopa 145 MG Extended Release Oral Capsule
Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1600775
8 HR carbidopa 61.25 MG / levodopa 245 MG Extended Release Oral Capsule
Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1600916
8 HR carbidopa 23.75 MG / levodopa 95 MG Extended Release Oral Capsule
Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1600773
carbidopa 70 MG / levodopa 280 MG Extended Release Oral Capsule
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2690284
carbidopa 87.5 MG / levodopa 350 MG Extended Release Oral Capsule
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2690290
carbidopa 52.5 MG / levodopa 210 MG Extended Release Oral Capsule
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2690279
carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2690259
carbidopa 25 MG / levodopa 100 MG Disintegrating Oral Tablet
Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 476399
carbidopa 4.63 MG/ML / levodopa 20 MG/ML Oral Suspension
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1599846
10 ML foscarbidopa 12 MG/ML / foslevodopa 240 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2695782
carbidopa 25 MG / levodopa 250 MG Disintegrating Oral Tablet
Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 476515
carbidopa 10 MG / levodopa 100 MG Disintegrating Oral Tablet
Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 483090
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Levodopa and Carbidopa, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 75 of 366 listed Levodopa and Carbidopa NDCs with Medicaid activity.
Compare Levodopa and Carbidopa products
A representative set of FDA-listed product records for Levodopa and Carbidopa — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Extended-release capsule | ||||
| CARBIDOPA HYDRATE 35 mg/1; LEVODOPA 140 mg | Oral | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| CARBIDOPA HYDRATE 52.5 mg/1; LEVODOPA 210 mg | Oral | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| CARBIDOPA HYDRATE 70 mg/1; LEVODOPA 280 mg | Oral | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| CARBIDOPA HYDRATE 87.5 mg/1; LEVODOPA 350 mg | Oral | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| LEVODOPA 95 mg/1; CARBIDOPA HYDRATE 23.75 mg | Oral | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| LEVODOPA 145 mg/1; CARBIDOPA HYDRATE 36.25 mg | Oral | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| LEVODOPA 195 mg/1; CARBIDOPA HYDRATE 48.75 mg | Oral | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| LEVODOPA 245 mg/1; CARBIDOPA HYDRATE 61.25 mg | Oral | Amneal Pharmaceuticals LLC | NDA | View NDC → |
| CARBIDOPA 23.75 mg/1; LEVODOPA 95 mg | Oral | Remedyrepack Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| CARBIDOPA 36.25 mg/1; LEVODOPA 145 mg | Oral | Remedyrepack Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| CARBIDOPA 48.75 mg/1; LEVODOPA 195 mg | Oral | Remedyrepack Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| CARBIDOPA 61.25 mg/1; LEVODOPA 245 mg | Oral | Remedyrepack Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| CARBIDOPA 23.75 mg/1; LEVODOPA 95 mg | Oral | Zydus Pharmaceuticals USA Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| CARBIDOPA 36.25 mg/1; LEVODOPA 145 mg | Oral | Zydus Pharmaceuticals USA Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| CARBIDOPA 48.75 mg/1; LEVODOPA 195 mg | Oral | Zydus Pharmaceuticals USA Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| CARBIDOPA 61.25 mg/1; LEVODOPA 245 mg | Oral | Zydus Pharmaceuticals USA Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 💊Extended-release tablet | ||||
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Accord Healthcare, Inc. | ANDA | View NDC → |
| CARBIDOPA 50 mg/1; LEVODOPA 200 mg | Oral | Accord Healthcare, Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Advagen Pharma Ltd | ANDA | View NDC → |
| CARBIDOPA 50 mg/1; LEVODOPA 200 mg | Oral | Advagen Pharma Ltd | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| CARBIDOPA 50 mg/1; LEVODOPA 200 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| CARBIDOPA 50 mg/1; LEVODOPA 200 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| CARBIDOPA HYDRATE 25 mg/1; LEVODOPA 100 mg | Oral | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| CARBIDOPA HYDRATE 50 mg/1; LEVODOPA 200 mg | Oral | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| CARBIDOPA 50 mg/1; LEVODOPA 200 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Mylan Institutional Inc. | ANDA | View NDC → |
| CARBIDOPA 50 mg/1; LEVODOPA 200 mg | Oral | Mylan Institutional Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| CARBIDOPA 50 mg/1; LEVODOPA 200 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | View NDC → |
| CARBIDOPA 50 mg/1; LEVODOPA 200 mg | Oral | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Radha Pharmaceuticals Inc | ANDA | View NDC → |
| CARBIDOPA 50 mg/1; LEVODOPA 200 mg | Oral | Radha Pharmaceuticals Inc | ANDA | View NDC → |
| CARBIDOPA HYDRATE 25 mg/1; LEVODOPA 100 mg | Oral | Safecor Health, LLC | ANDA | View NDC → |
| CARBIDOPA HYDRATE 50 mg/1; LEVODOPA 200 mg | Oral | Safecor Health, LLC | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | ScieGen Pharmaceuticals Inc | ANDA | View NDC → |
| CARBIDOPA 50 mg/1; LEVODOPA 200 mg | Oral | ScieGen Pharmaceuticals Inc | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| CARBIDOPA 50 mg/1; LEVODOPA 200 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 💊Orally disintegrating tablet | ||||
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 💊Oral suspension | ||||
| LEVODOPA 20 mg/mL; CARBIDOPA HYDRATE 4.63 mg/mL | Enteral | AbbVie Inc. | NDA | View NDC → |
| 💊Tablet | ||||
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | A-S Medication Solutions | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | A-S Medication Solutions × 6 listings | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | Advagen Pharma Ltd., | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Advagen Pharma Ltd., | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | Advagen Pharma Ltd., | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | American Health Packaging | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | American Health Packaging | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | American Health Packaging | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Aphena Pharma Solutions - Tennessee, LLC × 3 listings | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | AvKARE | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | AvKARE | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | AvKARE | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | AvPAK | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| CARBIDOPA HYDRATE 25 mg/1; LEVODOPA 100 mg | Oral | Cardinal Health 107, LLC | ANDA | View NDC → |
| CARBIDOPA HYDRATE 25 mg/1; LEVODOPA 250 mg | Oral | Cardinal Health 107, LLC | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | Coupler LLC | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Coupler LLC | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | Coupler LLC × 3 listings | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | Dr. Reddy's Laboratories Inc | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Dr. Reddy's Laboratories Inc | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | Dr. Reddy's Laboratories Inc | ANDA | View NDC → |
| CARBIDOPA HYDRATE 25 mg/1; LEVODOPA 100 mg | Oral | Major Pharmaceuticals | ANDA | View NDC → |
| CARBIDOPA HYDRATE 25 mg/1; LEVODOPA 250 mg | Oral | Major Pharmaceuticals | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | NuCare Pharmaceuticals,Inc. | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | Organon LLC | NDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Organon LLC | NDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | Proficient Rx LP | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Proficient Rx LP | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | Proficient Rx LP | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | Remedyrepack Inc. | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | ScieGen Pharmaceuticals Inc | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | ScieGen Pharmaceuticals Inc | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | ScieGen Pharmaceuticals Inc | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| CARBIDOPA HYDRATE 10 mg/1; LEVODOPA 100 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| CARBIDOPA HYDRATE 25 mg/1; LEVODOPA 100 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| CARBIDOPA HYDRATE 25 mg/1; LEVODOPA 250 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | TruPharma, LLC | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | TruPharma, LLC | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | TruPharma, LLC | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | Westminster Pharmaceuticals, LLC | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | Westminster Pharmaceuticals, LLC | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | Westminster Pharmaceuticals, LLC | ANDA | View NDC → |
| CARBIDOPA 10 mg/1; LEVODOPA 100 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 100 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| CARBIDOPA 25 mg/1; LEVODOPA 250 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
Showing 118 of 118 products — FDA National Drug Code Directory. See every product, package size and price: browse all 118 Levodopa and Carbidopa NDCs →
Levodopa and Carbidopa side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Levodopa and Carbidopa — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Levodopa and Carbidopa in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Levodopa and Carbidopa FDA approval history
How Levodopa and Carbidopa went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Levodopa and Carbidopa recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Levodopa and Carbidopa recalls since July 2021.
✅No Levodopa and Carbidopa recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
Levodopa and Carbidopa supply and shortage status
Whether Levodopa and Carbidopa is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Levodopa and Carbidopa costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet · Oral | 25; 100 mg/1; mg | $0.076 per tablet | NDC details & price history |
| Tablet · Oral | 10; 100 mg/1; mg | $0.068 per tablet | NDC details & price history |
| Tablet · Oral | 25; 250 mg/1; mg | $0.119 per tablet | NDC details & price history |
| Tablet · Oral | CARBIDOPA HYDRATE 25 mg/1; LEVODOPA 100 mg | $0.076 per tablet | NDC details & price history |
| Tablet · Oral | CARBIDOPA HYDRATE 25 mg/1; LEVODOPA 250 mg | $0.119 per tablet | NDC details & price history |
| Tablet, Extended Release · Oral | 25; 100 mg/1; mg | $0.110 per tablet | NDC details & price history |
| Tablet, Extended Release · Oral | CARBIDOPA 25 mg/1; LEVODOPA 100 mg | $0.110 per tablet | NDC details & price history |
| Tablet, Extended Release · Oral | CARBIDOPA 50 mg/1; LEVODOPA 200 mg | $0.180 per tablet | NDC details & price history |
| Tablet, Extended Release · Oral | 50; 200 mg/1; mg | $0.180 per tablet | NDC details & price history |
| Capsule, Extended Release · Oral | 61.25; 245 mg/1; mg | $5.00 per capsule | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Levodopa and Carbidopa brand names
Levodopa and Carbidopa is sold under 5 brand names in the FDA directory — Duopa, Rytary, Sinemet, Parcopa and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Levodopa and Carbidopa: manufacturers and labelers
36 companies list Levodopa and Carbidopa products with the FDA. By number of product records, the largest are Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries, Inc., A-S Medication Solutions. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
…and 12 more on the FDA NDC directory.
Levodopa and Carbidopa drug class (RxNorm)
Levodopa and Carbidopa belongs to the Aromatic Amino Acid Decarboxylation Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Levodopa and Carbidopa page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Remedyrepack Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →